Internal Medicine, Endocrinology, Diabetes, & Metabolism · West Palm Beach, FL
NPI
1003820002
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
1515 N Flagler Dr, Suite 430
West Palm Beach, FL, 33401
Phone (561) 659-6336
Groups this clinician bills Medicare through
Medicare paid, 2024
$738K
35,681 services
Medicare patients, 2024
1,072
Average age 76
Drug cost, 2024
$3.9M
8,458 prescriptions
Company payments, 2025
$100K
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by William Kaye was code 36415 (venipuncture blood collection), 2,404 times for 974 patients. In total William Kaye billed 35,681 services in 86 codes, and Medicare paid $738K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-03-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 36415 Venipuncture Blood Collection | Office | 2,404 | 974 | $8.64 | $21K |
| 99214 Office E&M - Established | Office | 2,293 | 927 | $96.29 | $221K |
| J0897 Injection, denosumab, 1 mg | Office | 2,280 | 29 | $20.91 | $48K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 2,231 | 1,000 | $12.77 | $28K |
| 80053 Clinical Chemistry | Office | 1,878 | 847 | $10.34 | $19K |
| 80061 Clinical Chemistry | Office | 1,522 | 760 | $13.10 | $20K |
| 85025 Blood Count | Office | 1,485 | 757 | $7.60 | $11K |
| 81003 Clinical Chemistry | Office | 1,454 | 694 | $2.20 | $3,194 |
| 82044 Clinical Chemistry | Office | 1,382 | 662 | $6.11 | $8,438 |
| 82570 Clinical Chemistry | Office | 1,380 | 661 | $5.08 | $7,005 |
| 84443 Clinical Chemistry | Office | 1,354 | 752 | $16.45 | $22K |
| 84439 Clinical Chemistry | Office | 1,268 | 716 | $8.83 | $11K |
| 82985 Clinical Chemistry | Office | 1,128 | 460 | $16.39 | $18K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 1,071 | 109 | $50.51 | $54K |
| 84378 Clinical Chemistry | Office | 1,037 | 455 | $11.29 | $12K |
By year: 2022 $668K for 40,957 services; 2023 $582K for 24,306 services; 2024 $738K for 35,681 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 2,404 | 974 | $8.64 | $21K |
| 80053 Clinical Chemistry | 1,878 | 847 | $10.34 | $19K |
| 80061 Clinical Chemistry | 1,522 | 760 | $13.10 | $20K |
| 85025 Blood Count | 1,485 | 757 | $7.60 | $11K |
| 81003 Clinical Chemistry | 1,454 | 694 | $2.20 | $3,194 |
| 82044 Clinical Chemistry | 1,382 | 662 | $6.11 | $8,438 |
| 82570 Clinical Chemistry | 1,380 | 661 | $5.08 | $7,005 |
| 84443 Clinical Chemistry | 1,354 | 752 | $16.45 | $22K |
| 84439 Clinical Chemistry | 1,268 | 716 | $8.83 | $11K |
| 82985 Clinical Chemistry | 1,128 | 460 | $16.39 | $18K |
Medicare prescription drug claims, 2024
In 2024, the drug William Kaye prescribed most often to Medicare patients was Ozempic (Semaglutide), with 892 prescriptions and refills. In total William Kaye wrote 8,458 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 892 | 1,471 | 181 | $1.4M |
| Metformin Hcl Generic | 668 | 1,953 | 209 | $4,313 |
| Synthroid Levothyroxine Sodium | 469 | 1,288 | 139 | $57K |
| Mounjaro Tirzepatide | 391 | 485 | 74 | $502K |
| Jardiance Empagliflozin | 386 | 913 | 116 | $514K |
| Unithroid Levothyroxine Sodium | 370 | 1,062 | 113 | $11K |
| Levothyroxine Sodium Generic | 320 | 917 | 121 | $3,544 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 227 | 634 | 94 | $22K |
| Rosuvastatin Calcium Generic | 223 | 664 | 79 | $3,978 |
| Atorvastatin Calcium Generic | 216 | 642 | 68 | $1,850 |
| Metformin Hcl Er Metformin Hcl | 207 | 594 | 64 | $1,809 |
| Losartan Potassium Generic | 176 | 517 | 59 | $1,277 |
| Ezetimibe Generic | 156 | 455 | 48 | $4,058 |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | 148 | 347 | 41 | $134K |
| Trulicity Dulaglutide | 133 | 194 | 28 | $176K |
Brand drugs: 4,143 claims; generic drugs: 3,755 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid William Kaye $100K ($100K in general payments such as food, travel and fees) from 25 companies. The largest payer was Lilly USA, LLC with $62K.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 53 | $62K |
| Novo Nordisk Inc NVO | 36 | $25K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 14 | $11K |
| Sequel Med Tech, LLC | 6 | $259 |
| Amgen Inc. AMGN | 23 | $223 |
| Dexcom, Inc. DXCM | 4 | $192 |
| Neurocrine BioSciences, Inc. NBIX | 4 | $181 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 7 | $162 |
| Sanofi-Aventis U.S. LLC SNY | 6 | $155 |
| Madrigal Pharmaceuticals MDGL | 4 | $123 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.